Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127019261 | 12701926 | 1 | I | 0 | 20160830 | 20160830 | DIR | 76.00 | YR | F | N | 134.00000 | LBS | 20160829 | N | MD | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127019261 | 12701926 | 1 | PS | WELLBUTRIN XL | BUPROPION HYDROCHLORIDE | 1 | Oral | Y | D | 0 | 150 | MG | QD | ||||||
| 127019261 | 12701926 | 3 | C | TRANXENE T-TAB | CLORAZEPATE DIPOTASSIUM | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127019261 | 12701926 | 1 | Major depression |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127019261 | 12701926 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127019261 | 12701926 | Anhedonia | |
| 127019261 | 12701926 | Asthenia | |
| 127019261 | 12701926 | Depression | |
| 127019261 | 12701926 | Disturbance in attention | |
| 127019261 | 12701926 | Product substitution issue | |
| 127019261 | 12701926 | Psychomotor retardation |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | CASEID | RPSR COD |
|---|---|---|
| 127019261 | 12701926 | HP |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127019261 | 12701926 | 1 | 3 | MON |